% | $
Quotes you view appear here for quick access.

Rockwell Medical, Inc. Message Board

  • hymanroz hymanroz Jan 12, 2014 9:24 AM Flag

    Kerx vs. RMTI ....????

    KERX at this point has pretty much priced in approval of Zerenex. RMTI is extremely undervalued and makes for a much better investment at is current valuation. Though I feel Kerx will continue to move higher it is RMTI that will bring you a better ROI in the coming months. Many of you are getting way to emotional when it comes to the debate of kerx or RMTI. Both have a very bright future and lets remember that these drugs are going to be able to make a lot of very sick people have a better quality of life.....That is the issue at hand and that is the only mitigating factor that has any relevancy !!!!!! STAY THIRSTY MY BROTHERS !!!!!!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • own both instead of debating which is better.

    • hello there...

      : )

      • 1 Reply to waiting4kerx
      • FDA okays Vifor Fresenius phosphate binder Velphoro
        World News | November 28, 2013T
        Kevin Grogan

        The US Food and Drug Administration has given the green light to Vifor Fresenius Medical Care Renal Pharma's hyperphosphatemia drug Velphoro.

        The approval for Velphoro (sucroferric oxyhydroxide), formerly known as PA21, is based on Phase III data demonstrated that the drug successfully controls the accumulation of phosphorus in the blood with the advantage of a much lower pill burden than the current standard of care in patients with chronic kidney disease on dialysis, namely Sanofi's Renvela (sevelamer carbonate).
        On average, dialysis patients take 19 pills per day with phosphate binders making up about 50% of that. The recommended starting dose of Velphoro is three tablets per day (i.e. one per meal) so compliance should improve considerably.

        UPDATE: Vifor Fresenius Medical Care Renal Pharma chief executive Charles DeLoach told PharmaTimes that as well as reducing the pill burden, he noted that the company asked a Swiss university to do tests so that they get the right balance between having enough pliability to keep the tablet intact yet soft enough so that it can be chewed easily, a problem for many dialysis patients.
        Mr DeLoach noted that the company also did extensive taste tests in dialysis patients (many of whom suffer from altered taste buds) and of all the tastes, "by far and away" the favourite was the wildberry flavour used for Velphoro. "When you give patients something that is easy to take that tastes good, the odds of them taking the medication are much higher".

        Velphoro was developed by Vifor Pharma and in 2011, all rights were transferred to Vifor Fresenius Medical Care Renal Pharma. It will be launched in the USA by Fresenius Medical Care North America in 2014.

    • KERX seems to be winning in the SP value race. Why do they have a higher price target than RMTI?

    • Does Kerx & RMTI compete with each other? Does a patient have a choice of tanking one or the other or are their drugs used for different purposes. I raise this question as many of the posts on this message board makes it sounds like they do. But what I read of Kerx they do not.

      Sentiment: Strong Buy

11.97-0.16(-1.32%)Dec 1 4:00 PMEST